Metropolis Healthcare shines on acquiring Ambika Pathology in Kolhapur
Metropolis Healthcare is currently trading at Rs. 2133.80, up by 88.15 points or 4.31% from its previous closing of Rs. 2045.65 on the BSE.
The scrip opened at Rs. 2023.05 and has touched a high and low of Rs. 2152.60 and Rs. 2023.05 respectively. So far 4487 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2306.85 on 10-Oct-2024 and a 52 week low of Rs. 1383.70 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2152.60 and Rs. 2015.00 respectively. The current market cap of the company is Rs. 11061.41 crore.
The promoters holding in the company stood at 48.89%, while Institutions and Non-Institutions held 45.23% and 5.88% respectively.
Metropolis Healthcare has acquired Dr. R.S. Patil’s Ambika Pathology Laboratory (Ambika Pathology) in Kolhapur. This marks a key milestone in Metropolis’ ‘String of Pearls’ strategy, which focuses on building strong regional clusters and expanding access to advanced diagnostics across India.
Established in 1995, Ambika Pathology Laboratory has built a strong reputation for quality, accuracy, and patient-centric care. The facility operates a central laboratory supported by 12 patient touchpoints and offers a comprehensive portfolio of tests. With nearly 75% of its revenue derived from B2C walk-in patients, Ambika has earned the trust of both patients and clinicians across Kolhapur and neighbouring towns. Its strong local connect makes it a strategic addition to Metropolis’ Western Maharashtra cluster, where the company already operates 19 laboratories across Pune, Kolhapur, Sangli, Satara, Solapur, Nashik, and Ahmednagar, supported by more than 200 patient service centres and a growing franchise network.
Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services.
